One of the key factors associated with ACT to induce a durable clinical response is the persistence of tumour-reactive T cells following T-cell infusion.26 Previously, we observed a differential capacity of day-10 and day-20 CD4+ Th1 cells to enhance the antitumour response of CD8+ CTLs. Here, CD8A is linked to neoplasm.